Provided is a method for identifying an administration target using gene expression amounts at mRNA level as an indicator, in the case of administering an anti-hTROP2 antibody-containing medicine to a human patient suffering from cancer. The present invention pertains to a method for identifying a target for the administration of an anti-hTROP2 antibody-containing medicine to a human patient suffering from cancer, said method comprising: a step for collecting a biological sample from a human patient diagnosed as having cancer； a step for evaluating the expression amount of hTROP2 gene at mRNA level in the biological sample； a step for, when the biological sample is determined as having a high expression amount of hTROP2 gene, then evaluating the expression amount of SLFN11 gene at mRNA level therein； and a step for, when the biological sample is determined as having a high expression amount of SLFN11 gene, then identifying the human patient as a target for the administration of the anti-hTROP2 antibody-containing medicine. Alternatively, the aforesaid method comprises: a step for collecting a biological sample from a human patient diagnosed as having cancer； a step for evaluating the expression amounts of hTROP2 gene and SLFN11 gene at mRNA level in the biological sample； and a step for, when the biological sample is determined as having high expression amounts of hTROP2 gene and SLFN11 gene, then identifying the human patient as a target for the administration of the anti-hTROP2 antibody-containing medicine.本發明提供一種方法，其在罹患癌的人類患者中，在投予含有抗hTROP2抗體的醫藥之際，將於mRNA層級的基因表現量作為指標而辨識投予對象。本發明係關於在罹患癌的人類患者中，辨識投予含有抗hTROP2抗體之醫藥的對象之方法，該方法包含:從被診斷罹患癌的人類患者取得活體樣本之步驟；評價在該活體樣本中於mRNA層級的hTROP2基因的表現量之步驟；在hTROP2基因的表現量被判斷為高之該活體樣本中評價於mRNA層級的SLFN11基因的表現量之步驟；及將具有SLFN11基因的表現量被判斷為高之該活體樣本的人類患者辨識作為投予含有抗hTROP2抗體的醫藥的對象之步驟。又，該方法包含從被診斷罹患癌的人類患者取得活體樣本之步驟；評價在該樣本中於mRNA層級的hTROP2基因及SLFN11基因的表現量之步驟；及將具有hTROP2基因及SLFN11基因的表現量被判斷為高之該樣本的人類患者辨識作為投予含有抗hTROP2抗體之醫藥的對象之步驟。
